Advertisement

Establishment of Novel Monoclonal Fabs Specific for Epstein-Barr Virus Encoded Latent Membrane Protein 1

  • Gaoxin Li
  • Ling Ding
  • Xiaojing Ma
  • Qiliang Cai
  • Tianlei Ying
  • Fang WeiEmail author
Letter
  • 25 Downloads

Dear Editor,

Epstein-Barr virus (EBV, also termed human herpesvirus-4) was the first identified human tumor virus. Since its discovery in 1964, studies have shown that EBV infects over 90% of all people by the time they are adults (Williams and Crawford 2006). EBV infection can result in mucocutaneous and systemic diseases, ranging from self-limited illnesses to aggressive malignancies, including B cell Hodgkin lymphoma and nasopharyngeal carcinoma. In vitro, EBV transforms resting B cells into proliferating blast cells (Pope et al. 1968). This transformation depends on the expression of nine viral latent proteins, including latent membrane protein 1 (LMP1). LMP1 expression in B lymphocytes can constitutively result in lymphoma. EBV-positive tumors express LMP1 on their surface (Deacon et al. 1993). These findings have implicated LMP1 as a suitable target for immunotherapy to treat EBV related Hodgkin lymphoma and nasopharyngeal carcinoma.

LMP1 is a membrane protein composed of a...

Notes

Acknowledgements

This work was supported by the National Natural Science Foundation of China (Grant Numbers: 81402542 and 81772166) and the scholarship of Pujiang Talents in Shanghai to Fang Wei (Grant Number: 14PJ1405600).

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.

Animal and Human Rights Statement

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

  1. Chen R, Zhang D, Mao Y, Zhu J, Ming H, Wen J, Ma J, Cao Q, Lin H, Tang Q, Liang J, Feng Z (2012) A human Fab-based immunoconjugate specific for the LMP1 extracellular domain inhibits nasopharyngeal carcinoma growth in vitro and in vivo. Mol Cancer Ther 11:594–603CrossRefGoogle Scholar
  2. Cho HI, Kim UH, Shin AR, Won JN, Lee HJ, Sohn HJ, Kim TG (2018) A novel Epstein–Barr virus-latent membrane protein-1-specific T-cell receptor for TCR gene therapy. Br J Cancer 118:534–545CrossRefGoogle Scholar
  3. Deacon EM, Pallesen G, Niedobitek G, Crocker J, Brooks L, Rickinson AB, Young LS (1993) Epstein–Barr virus and Hodgkin’s disease: transcriptional analysis of virus latency in the malignant cells. J Exp Med 177:339–349CrossRefGoogle Scholar
  4. Dirmeier U, Neuhierl B, Kilger E, Reisbach G, Sandberg ML, Hammerschmidt W (2003) Latent membrane protein 1 is critical for efficient growth transformation of human B cells by Epstein–Barr virus. Cancer Res 63:2982–2989Google Scholar
  5. Fennewald S, van Santen V, Kieff E (1984) Nucleotide sequence of an mRNA transcribed in latent growth-transforming virus infection indicates that it may encode a membrane protein. J Virol 51:411–419Google Scholar
  6. Gires O, Zimber-Strobl U, Gonnella R, Ueffing M, Marschall G, Zeidler R, Pich D, Hammerschmidt W (1997) Latent membrane protein 1 of Epstein–Barr virus mimics a constitutively active receptor molecule. EMBO J 16:6131–6140CrossRefGoogle Scholar
  7. Hislop AD, Taylor GS, Sauce D, Rickinson AB (2007) Cellular responses to viral infection in humans: lessons from Epstein–Barr virus. Annu Rev Immunol 25:587–617CrossRefGoogle Scholar
  8. Kaye KM, Devergne O, Harada JN, Izumi KM, Yalamanchili R, Kieff E, Mosialos G (1996) Tumor necrosis factor receptor associated factor 2 is a mediator of NF-kappa B activation by latent infection membrane protein 1, the Epstein–Barr virus transforming protein. Proc Natl Acad Sci U S A 93:11085–11090CrossRefGoogle Scholar
  9. Kutz H, Reisbach G, Schultheiss U, Kieser A (2008) The c-Jun N-terminal kinase pathway is critical for cell transformation by the latent membrane protein 1 of Epstein–Barr virus. Virology 371:246–256CrossRefGoogle Scholar
  10. Lin X, Gudgeon NH, Hui EP, Jia H, Qun X, Taylor GS, Barnardo MC, Lin CK, Rickinson AB, Chan AT (2008) CD4 and CD8 T cell responses to tumour-associated Epstein–Barr virus antigens in nasopharyngeal carcinoma patients. Cancer Immunol Immunother 57:963–975CrossRefGoogle Scholar
  11. Lu ZX, Ma XQ, Yang LF, Wang ZL, Zeng L, Li ZJ, Li XN, Tang M, Yi W, Gong JP, Sun LQ, Cao Y (2008) DNAzymes targeted to EBV-encoded latent membrane protein-1 induce apoptosis and enhance radiosensitivity in nasopharyngeal carcinoma. Cancer Lett 265:226–238CrossRefGoogle Scholar
  12. Omar N, Lim TS (2018) Construction of naive and immune human Fab phage-display library. Methods Mol Biol 1701:25–44CrossRefGoogle Scholar
  13. Pope JH, Horne MK, Scott W (1968) Transformation of foetal human keukocytes in vitro by filtrates of a human leukaemic cell line containing herpes-like virus. Int J Cancer 3:857–866CrossRefGoogle Scholar
  14. Williams H, Crawford DH (2006) Epstein–Barr virus: the impact of scientific advances on clinical practice. Blood 107:862–869CrossRefGoogle Scholar
  15. Xiao X, Ho M, Zhu Z, Pastan I, Dimitrov DS (2009) Identification and characterization of fully human anti-CD22 monoclonal antibodies. MAbs 1:297–303CrossRefGoogle Scholar
  16. Ying T, Du L, Ju TW, Prabakaran P, Lau CC, Lu L, Liu Q, Wang L, Feng Y, Wang Y, Zheng BJ, Yuen KY, Jiang S, Dimitrov DS (2014) Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. J Virol 88:7796–7805CrossRefGoogle Scholar
  17. Young LS, Rickinson AB (2004) Epstein–Barr virus: 40 years on. Nat Rev Cancer 4:757–768CrossRefGoogle Scholar

Copyright information

© Wuhan Institute of Virology, CAS 2019

Authors and Affiliations

  1. 1.Sheng Yushou Center of Cell Biology and Immunology, School of Life Sciences and BiotechnologyShanghai Jiaotong UniversityShanghaiChina
  2. 2.MOE & MOH Key Laboratory of Medical Molecular Virology, School of Basic Medicine, Shanghai Medical CollegeFudan UniversityShanghaiChina

Personalised recommendations